Le Lézard
Classified in: Health
Subject: FDA

Nextremity Solutions, Inc. Receives FDA 510(k) Clearance for Stratumtm Foot Plating System


WARSAW, Ind., April 3, 2019 /PRNewswire-PRWeb/ -- Nextremity Solutions, Inc., a strategic commercialization organization with a focus on the musculoskeletal space, located in "The Orthopedic Capital of the World," Warsaw, Ind., today announced it has recently received 510(k) clearance by the Food & Drug Administration to market its upcoming Stratum Foot Plating System.

Ryan Schlotterback, Chief Technology Officer of Nextremity Solutions said, "This is an important milestone for our company and the largest system we've brought to market to date. The team has spent a tremendous amount of effort with our surgeons to develop a comprehensive foot plating system that includes several innovative components; all working together to make foot plating simpler and more reproducible. The system includes implants with specific features that, along with a bicortical compression system, eliminate the decade's old compression slots. We believe these features, along with a host of others, create efficiency and stability not seen before in foot plating. The team has achieved all of this with an efficient and fully disposable instrument set. The Stratum Foot Plating system will be an important platform as we continue to develop our product portfolio."

"We are very excited about initial responses we are receiving from surgeons. Specifically, surgeons are intrigued by the unique tines that give the surgeon the ability to manipulate small bones and free up hands during the case. They also see tremendous value in the innovative external compression ramp that helps generate bicortical, linear compression. The unique features of the comprehensive Stratum Foot Plating System truly make it the next generation in plating," said Mike Coon, Chief Commercial Integration Officer for Nextremity Solutions.

The Nextremity Solutions Stratum Foot Plating System is a plate and screws construct indicated for fixation of fractures, osteotomies, non-unions, malunions and fusions of small bones and small bone segments, particularly in osteopenic bone. An application for a CE mark is pending.

About Nextremity Solutions, Inc.

Nextremity Solutions, Inc. is a privately held strategic commercialization organization with a focus on the musculoskeletal space, offering innovative solutions and Revenue Ready® products for various musculoskeletal applications and for the benefit of our industry partners. The Company's procedure-ready, sterile implant systems include uniquely precise, proprietary technology designed to achieve repeatable and superior clinical outcomes.

For further information, visit https://www.nextremitysolutions.com/ or call Dave Temple, Executive Director of Marketing & Communications at 574-635-3022.

 

SOURCE Nextremity Solutions, Inc.


These press releases may also interest you

at 05:37
According to the new market research report "Cosmetic Pigments Market by Composition (Organic, Inorganic), Type (Special Effect, Surface treated, Nano), Application (Facial Makeup, Eye Makeup, Lip Products, Nail Products, Hair Color Products), and...

at 05:31
According to a recent report by Transparency Market Research, the global Prenatal Vitamin Supplements Market is expected to witness a substantial growth during the forecast period of 2016 to 2024. The growth of the market is the result of rising...

at 05:00
The Right Step names DeLisa Duncan Russell, LSW, LPC-S, as executive director of its Houston addiction treatment center. Russell has a long career working with complex addiction issues within the military, the religious community and in private...

at 04:52
BioInvent International AB's (publ) (OMXS: BINV) partner Oxurion NV has today reported topline data from a Phase lla study evaluating THR-317, a humanized antibody against placental growth factor (PlGF), in combination with anti-VEGF (ranibizumab),...

at 04:00
NanoValent Pharmaceuticals, Inc., a development stage cancer focused pharmaceutical company progressing a new class of therapeutic agents called targeted nanospheres (TNS), today announced the acceptance and formal publication of United States Patent...

at 04:00
STORM Therapeutics, the drug discovery company focused on the discovery of small molecule therapeutics modulating RNA epigenetics, today announced that it will be hosting an international conference focused on the emerging field of "RNA epigenetics"....



News published on 3 april 2019 at 11:00 and distributed by: